Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.5582
−$0.0468 · -7.74%
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Previous close
$0.5582
−$0.0468 · -7.74%
After-hours
$0.57
+$0.0118 · +2.11%
Oct 8, 7:14 PM ET
Regular session · ET · Market data may be delayed.
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Day range
Current $0.5582
52-week range
Current $0.5582
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
48
Fair Value
Sentiment
66
Bullish
Risk
77
High Risk
Momentum
23
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Day range
Current $0.5582
52-week range
Current $0.5582
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 1.5M USD | 583.23K USD | — | — |
| Cost of goods sold | — | 9.36M USD | 7.05K USD | 16.4M USD | 271.68K USD |
| Gross profit | — | −7.86M USD | 576.18K USD | −16.4M USD | −271.68K USD |
| Research and development | 7.04M USD | 9.36M USD | 7.63M USD | 92.42M USD | 23.9M USD |
| Selling, general, and administrative | 6.48M USD | 6.46M USD | 8.42M USD | 20.97M USD | 13.55M USD |
| Operating expenses | 13.23M USD | 6.46M USD | 16.05M USD | 96.99M USD | 37.17M USD |
| Interest income | 652.09K USD | 1.29M USD | 1.22M USD | 448.67K USD | 1.65K USD |
| Interest expense | — | — | — | 448.67K USD | — |
| Depreciation and amortization | 21.72K USD | 22.32K USD | 7.05K USD | 186.45K USD | 271.68K USD |
| Operating income | −13.23M USD | −14.32M USD | −15.47M USD | −113.39M USD | −37.45M USD |
| Net income | −12.6M USD | −12.96M USD | −14.29M USD | −112.66M USD | −36.54M USD |
Company facts updated Oct 9, 2026.
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Feb 13, 2023 | 1:20 | — | — |
Effective Feb 13, 2023
1:20
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
